natgillin/translations-raw huggingface dataset:
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of grade ≥ 3 thrombocytopenia in the bortezomib treatment group (BR-CAP) as compared to the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
Pri bolnikih z MCL (študija LYM-3002) je bila pojavnost trombocitopenije stopnje 3 ali več v skupini, ki je prejemala bortezomib (BR-CAP), večja (56,7 % proti 5,8 %), v primerjavi s skupino, ki bortezomiba ni prejemala (rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon [RCHOP]).
In the Phase III study patients who received bortezomib subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment emergent adverse reactions that were grade 3 or higher in toxicity, and a 5% lower incidence of discontinuation of bortezomib.
V študiji faze III so imeli bolniki, ki so prejemali bortezomib subkutano za 13 % manjšo celokupno incidenco neželenih učinkov zaradi uporabe zdravila, s stopnjo toksičnosti 3 ali več in za 5 % manjšo pogostnost prekinitve zdravljenja v primerjavi z bolniki, ki so prejemali bortezomib intravensko.
Clinical efficacy in previously untreated mantle cell lymphoma (MCL) Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (BR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV).
V randomizirani, odprti študiji faze III, LYM-3002, so pri odraslih bolnikih s predhodno nezdravljenim MCL (stopnje II, III ali IV) primerjali učinkovitost in varnost bortezomiba v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom, vinkristinom in prednizonom (BR-CAP; n = 243) z zdravljenjem z rituksimabom, ciklofosfamidom, doksorubicinom, vinkristinom in prednizonom (R-CHOP; n = 244).
Combination therapy with melphalan and prednisone Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection in combination with oral melphalan and oral prednisone as shown in table 2.
Kombinirano zdravljenje z melfalanom in prednizonom Zdravilo Bortezomib Fresenius Kabi 3,5 mg prašek za raztopino za injiciranje se daje intravensko ali subkutano v kombinaciji s peroralnim melfalanom in prednizonom, kot je prikazano v preglednici 2.
• Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet,
• povečana občutljivost, odrevenelost, mravljinci ali pekoč občutek na koži ali bolečine v dlaneh in stopalih, zaradi poškodbe živca
Bortezomib is used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable.
Bortezomib se uporablja za zdravljenje limfoma plaščnih celic (redka oblika raka, ki prizadene bezgavke) pri bolnikih, starih 18 let in več, v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom in prednizonom, pri bolnikih, pri katerih bolezni še nismo zdravili in pri katerih presaditev krvotvornih matičnih celic ni primerna.
Table 7: Adverse reactions in patients with multiple myeloma treated with bortezomib in clinical trials and all post-marketing adverse reactions regardless of indication
Preglednica 7: Neželeni učinki pri bolnikih z diseminiranim plazmocitomom, zdravljenih z bortezomibom v kliničnih preskušanjih in v obdobju trženja, neodvisno od indikacije Organski sistem Pogostnost
Bortezomib was administered only in Blocks 1 and 2 to avoid potential overlapping toxicities with coadministered drugs in Block 3.
Bolniki so prejeli bortezomib le v 1. in 2. sklopu zdravljenja, da so se izognili prekrivanju toksičnih učinkov z drugimi, sočasno danimi zdravili v 3. sklopu zdravljenja.
You will have to take regular blood tests before and during your treatment with bortezomib, to check your blood cell counts regularly.
Pred in med zdravljenjem z bortezomibom vam bodo redno pregledovali kri, in tako spremljali število krvnih celic.
Bortezomib combination treatment with dexamethasone In the absence of any direct comparison between bortezomib and bortezomib in combination with dexamethasone in patients with progressive multiple myeloma, a statistical matched-pair analysis was conducted to compare results from the non randomised arm of bortezomib in combination with dexamethasone (Phase II open-label study MMY-2045), with results obtained in the bortezomib monotherapy arms from different Phase III randomised studies (M34101-039 [APEX] and DOXIL MMY-3001) in the same indication.
Zato je bila opravljena statistična analiza izenačenih parov, ki je primerjala rezultate nerandomizirane skupine zdravljene z bortezomibom v kombinaciji z deksametazonom (odprta študija faze II; MMY2045) z rezultati zdravljenja z bortezomibom v različnih študijah faze III (M34101-039 [APEX] in DOXIL MMY-3001) za enako indikacijo.
Day 1, 2, 3, 4 Day 8, 9, 10, 11Cycles 2 to 4
Dx 40 mg dan 1, 2, 3, 4 dan 8, 9, 10, 11cikel 2 do 4
Very common Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*
Zelo pogosti trombocitopenija*, febrilna nevtropenija, nevtropenija *, levkopenija*, anemija*, limfopenija*
IV on day 1; and prednisone 100 mg/m orally on day 1 through day 5 of the 21 day bortezomib treatment cycle.
na 1. dan in 100 mg/m prednizona peroralno na 1. do 5. dan 21-dnevnega cikla zdravljenja z bortezomibom.
If you have not been treated before for multiple myeloma, and you are not suitable for blood stem cell transplantation you will receive bortezomib together with two other medicines; melphalan and prednisone.
Če vam diseminiranega plazmocitoma še niso zdravili in presaditev krvotvornih matičnih celic za vas ni primerna, vam bodo bortezomib injicirali skupaj z zdraviloma melfalan in prednizon.
In B-ALL patients with relapse within 18 months of diagnosis (n=27) the CR rate was 67% (95% CI: 46, 84); the 4-month event free survival rate was 44% (95% CI: 26, 62).
Pri bolnikih z Bcelično ALL in relapsom v manj kot 18 mesecih po diagnozi (n = 27) je bil delež popolnih odgovorov 67 % (95 % CI: 46, 84) in delež 4-mesečnega preživetja bolnikov brez dogodkov 44 % (95 % CI: 26, 62).
Time to progression Events n (%) Median a
Čas do napredovanja bolezni dogodki n (%) mediana a
A 6-week period is considered a treatment cycle.
Šest tedensko obdobje predstavlja en cikel zdravljenja.
• Serious allergic reaction (anaphylactic shock) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse
• znaki hude alergijske reakcije (anafilaktični šok), ki lahko vključujejo oteženo dihanje, bolečino ali tiščanje v prsih in/ali omotico/omedlevico, hudo srbenje kože ali dvignjene bulice na koži,
Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m dose to patients with multiple myeloma (n=14 in the intravenous group, n=17 in the subcutaneous group), the total systemic exposure after repeat dose administration (AUClast) was equivalent for subcutaneous and intravenous administrations.
(n = 14 pri intravenski in n = 17 pri subkutani skupini) je bila skupna sistemska izpostavljenost po ponovljenem odmerku (AUCzadnji) ekvivalentna pri subkutanem in intravenskem dajanju.
• Infections, including pneumonia, respiratory infections, bronchitis, fungal infections,
• okužbe, vključno s pljučnico, okužba dihal, bronhitis, glivične okužbe, produktiven kašelj, gripi podobna bolezen
Uncommon Hepatotoxicity (inc liver disorder), Hepatitis*, Cholestasis
Občasni hepatotoksičnost (vključno z boleznimi jeter), hepatitis*, holestaza
If local injection site reactions occur following bortezomib subcutaneous injection, either a less concentrated bortezomib solution (bortezomib 3.5 mg to be reconstituted to 1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.
Če se po subkutanem injiciranju bortezomiba na mestu injiciranja pojavijo lokalne reakcije, se priporoča, da subkutano injicirate manj koncentrirano raztopino bortezomiba (1 mg/ml namesto 2,5 mg/ml) ali pa preidete na intravensko dajanje zdravila.
A median of 6 cycles was received by patients in both treatment arms with 14% of subjects in the BR-CAP group and 17% of patients in the R-CHOP group receiving 2 additional cycles.
14 % preiskovancev iz skupine BR-CAP in 17% bolnikov iz skupine R-CHOP je prejelo 2 dodatna cikla zdravljenja.
Concomitant medicinal products
FARMACEVTSKI PODATKI
Patients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in table 1 (see section 4.4).
Nevropatična bolečina in/ali periferna nevropatija Bolnike, ki imajo nevropatično bolečino in/ali periferno nevropatijo, povezano z jemanjem bortezomiba, zdravite v skladu s preglednico 1 (glejte poglavje 4.4).
Dysacusis (inc tinnitus)*
Pogosti disakuza (vključno s tinitusom)*
Progression Free Survival, months (95% CI)
Preživetje brez napredovanja bolezni, meseci (95% CI) razmerje tveganja (95% CI)
How to use Bortezomib Fresenius Kabi
Kako uporabljati zdravilo Bortezomib Fresenius Kabi
#, Deep vein thrombosis*, Haemorrhage*, Thrombophlebitis (inc superficial), Circulatory collapse (inc hypovolaemic shock), Phlebitis, Flushing*, Haematoma (inc perirenal)*, Poor peripheral circulation*, Vasculitis, Hyperaemia (inc ocular)*
#, globoka venska tromboza*, krvavitev*, tromboflebitis (vključno s površinskim), cirkulatorni kolaps (vključno s hipovolemičnim šokom), flebitis, pordelost, hematom (vključno s perirenalnim)*, slaba periferna prekrvavitev*, vaskulitis, hiperemija (vključno z očesno)*
Motor neuropathy*, Loss of consciousness (inc syncope), Dizziness*, Dysgeusia*, Lethargy, Headache*
Pogosti motorična nevropatija*, izguba zavesti (vključno s sinkopo), omotica*, disgevzija*, letargija, glavobol*
Bortezomib might cause tiredness, dizziness, fainting, or blurred vision.
Vpliv na sposobnost upravljanja vozil in strojev Bortezomib lahko povzroči utrujenost, omotičnost, omedlevico ali zamegljen vid.
Uncommon Pancytopenia*
Občasni pancitopenija*
Leukopenia*, Lymphopenia* Uncommon Pancytopenia*, Febrile neutropenia, Coagulopathy*, Leukocytosis*, Lymphadenopathy, Haemolytic anaemia
Občasni pancitopenija*, febrilna nevtropenija, koagulopatija*, levkocitoza*, limfadenopatija, hemolitična anemija
How to store Bortezomib Fresenius Kabi
Shranjevanje zdravila Bortezomib Fresenius Kabi
Bortezomib is used for the treatment of multiple myeloma (a cancer of the bone marrow) in patients older than 18 years: - alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
Bortezomib se uporablja za zdravljenje diseminiranega plazmocitoma (rak kostnega mozga) pri bolnikih, starejših od 18 let: - samostojno ali v kombinaciji s pegiliranim liposomskim doksorubicinom ali deksametazonom pri bolnikih, pri katerih je bolezen napredovala po tem, ko so prejeli vsaj eno predhodno vrsto zdravljenja in so jim že presadili krvotvorne matične celice ali presaditev krvotvornih matičnih celic pri njih ni primerna.
What Bortezomib Fresenius Kabi looks like and contents of the pack Bortezomib powder for solution for injection is a white to off-white lyophilized powder or cake.
Izgled zdravila Bortezomib Fresenius Kabi in vsebina pakiranja Bortezomib prašek za raztopino za injiciranje je bel do belkast liofiliziran prašek ali pogača .
If you are given bortezomib for the treatment of multiple myeloma the side effects you may get are listed below:
Če prejemate bortezomib za zdravljenje diseminiranega plazmocitoma, se lahko pri vas pojavijo naslednji neželeni učinki:
When bortezomib is given together with dexamethasone, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the bortezomib 21-day treatment cycle.
Če jemljete bortezomib skupaj z deksametazonom boste prejeli bortezomib v veno ali v podkožje v 21-dnevnem ciklu zdravljenja in 40 mg deksametazona peroralno na 1., 2., 3., 4., 8., 9., 10. in 11. dan cikla zdravljenja z bortezomibom.
Adverse reaction left and right ventricular)*, Arrhythmia*, Tachycardia*, Palpitations, Angina pectoris, Pericarditis (inc pericardial effusion)*, Cardiomyopathy*, Ventricular dysfunction*, Bradycardia
#, srčno-pljučni zastoj*, srčna fibrilacija (vključno z atrijsko), srčno popuščanje (vključno z levim in desnim prekatom)*, aritmija*, tahikardija*, palpitacije, angina pektoris, perikarditis (vključno s perikardialnim izlivom)*, kardiomiopatija*, disfunkcija prekata*, bradikardija
Dose adjustments for combination therapy for patients with progressive multiple myeloma For bortezomib dosage adjustments for combination therapy follow dose modification guidelines described under monotherapy above.
Prilagoditev odmerjanja pri kombiniranem zdravljenju bolnikov z diseminiranim plazmocitomom Za prilagoditev odmerjanja bortezomiba pri kombiniranem zdravljenju upoštevajte navodila, za samostojno zdravljenje, opisana zgoraj.
Seizure disorders*, Post herpetic neuralgia, Speech disorder*, Restless legs syndrome, Migraine, Sciatica, Disturbance in attention, Reflexes abnormal*, Parosmia
#, nevrotoksičnost, motnje s krči*, post-herpetična nevralgija, motnje govora*, sindrom nemirnih nog, migrena, išias, motnje pozornosti, nenormalni refleksi*, parozmija
Very common Thrombocytopenia*, Neutropenia*, Anaemia* Common
Zelo pogosti trombocitopenija*, nevtropenija*, anemija*
A Phase III randomised, parallel-group, open-label, multicentre study was conducted in 646 patients comparing the safety and efficacy of bortezomib plus pegylated liposomal doxorubicin versus bortezomib monotherapy in patients with multiple myeloma who had received at least 1 prior therapy and who did not progress while receiving anthracycline-based therapy.
Bortezomib v kombinaciji s pegiliranim liposomskim doksorubicinom (študija DOXIL-MMY-3001) Pri 646 bolnikih je bila opravljena randomizirana, odprta, multicentrična študija faze III pri vzporednih skupinah, v kateri so primerjali varnost in učinkovitost kombinirane terapije z bortezomibom in pegiliranim liposomskim doksorubicinom z monoterapijo z bortezomibom pri bolnikih z diseminiranim plazmocitomom, ki so že prejeli najmanj eno vrsto terapije in pri katerih bolezen ni napredovala med prejemanjem antraciklinske terapije.
• advice on how to reduce the risk of mix-up of IV and SC reconstituted syringes
• Navodilo kako zmanjšati možnost zamenjave injekcijskih brizg za i.v.
- If platelet counts < 25,000 cells/μL.
≥ 75.000 celic/μl.
Prednisone is given orally at 100 mg/m on days 1, 2, 3, 4 and 5 of the bortezomib treatment cycle.
Prednizon boste jemali peroralno v odmerku 100 mg/m na 1., 2., 3., 4. in 5. dan cikla zdravljenja z bortezomibom.
Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection bortezomib
Bortezomib Fresenius Kabi 3,5 mg prašek za raztopino za injiciranje bortezomib
Each 10 ml vial of bortezomib must be carefully reconstituted with 1.4 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper.
Vsako 10 ml vialo bortezomiba morate previdno rekonstituirati z 1,4 ml 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje.
* Primary endpoint a
* Primarna ocena učinkovitosti a
A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data from 21 patients.
Študija medsebojnega delovanja zdravil za učinkovine melfalan-prednizon na farmakokinetiko bortezomiba (intravensko) je pokazala 17 % zvečanje srednje vrednosti AUC bortezomiba (na osnovi podatkov 21 bolnikov).
9/l or ANC
9/l ali
(n=93) or ≤ 1.0 mg/m (n=37) and given on days 1, 4, 8 and 11 every 3 weeks for maximum of 8 cycles either as single agent or in combination with dexamethasone in accordance with the standard of care.
Zdavilo so prejemali na 1., 4., 8., in 11. dan vsake tri tedne, največ 8 ciklov zdravljenja kot samostojno zdravljenje ali v kombinaciji z deksametazonom, skladno s klinično prakso.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. PROIZVAJALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov proizvajalca, odgovornega za sproščanje serij Fresenius Kabi Deutschland GmbH
1.1 Preparation of the 3.5 mg vial: carefully add 3.5 ml of sterile, sodium chloride 9 mg/ml (0.9%) solution for injection to the vial containing the bortezomib powder by using a syringe of the appropriate size without removing the vial stopper.
1.1 Priprava 3,5 mg viale: previdno dodajte 3,5 ml sterilne 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje v vialo, ki vsebuje prašek bortezomib.
Dexamethasone is administered orally at 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12 of the bortezomib treatment cycle.
Deksametazon se jemlje peroralno v odmerku 20 mg na 1., 2., 4., 5., 8., 9., 11. in 12. dan cikla zdravljenja z bortezomibom.
Thalidomide is administered orally at 50 mg daily on days 1-14 and if tolerated the dose is increased to 100 mg on days 15-28, and thereafter may be further increased to 200 mg daily from cycle 2 (see table 4).
Če odmerek dobro prenaša se ga lahko poveča na 100 mg od 15. do 28. dneva in nato od 2. cikla zdravljenja naprej na 200 mg na dan (glejte preglednico 4).
1.1 Preparation of the 3.5 mg vial: carefully add 1.4 ml of sterile, sodium chloride 9 mg/ml (0.9%) solution for injection to the vial containing the bortezomib powder by using a syringe of the appropriate size without removing the vial stopper.
1.1 Priprava 3,5 mg viale: previdno dodajte 1,4 ml sterilne 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje v vialo, ki vsebuje prašek bortezomib.
Hypertension*, Hypotension*, Orthostatic
Pogosti hipertenzija*, hipotenzija*, ortostatska hipotenzija
When bortezomib is given in combination with other medicinal products, refer to their Summaries of Product Characteristics for additional contraindications.
Pri sočasni uporabi bortezomiba z drugimi zdravili, glejte Povzetke glavnih značilnosti teh zdravil za dodatne kontraindikacije.
Pegylated liposomal doxorubicin is administered at 30 mg/m on day 4 of the bortezomib treatment cycle as a 1 hour intravenous infusion administered after the bortezomib injection.
Pegilirani liposomski doksorubicin se daje v obliki 1-urne intravenske infuzije v odmerku 30 mg/m² na 4. dan cikla zdravljenja, po injiciranju bortezomiba.
In addition, when bortezomib is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these medicinal products should be considered in the event of toxicities, according to the recommendations in the respective Summary of Product Characteristics.
Kadar dajemo bortezomib v kombinaciji z drugimi kemoterapevtiki je v primeru pojava toksičnosti potrebno razmisliti o zmanjšanju odmerka teh zdravil, skladno z njihovimi povzetki glavnih značilnosti zdravil.
This medicine contains the active substance bortezomib, a so-called ‘proteasome inhibitor'.
Zdravilo Bortezomib Fresenius Kabi vsebuje učinkovino bortezomib, ki je zaviralec proteasomov.
Bortezomib treatment must be initiated under supervision of a physician experienced in the treatment of cancer patients, however bortezomib may be administered by a healthcare professional experienced in use of chemotherapeutic agents.
Bortezomib pa lahko aplicira tudi zdravstveno osebje, ki ima izkušnje z zdravljenjem s kemoterapevstkimi učinkovinami.
Each 10 ml vial of bortezomib must be carefully reconstituted with 3.5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper.
Vsako 10 ml vialo bortezomiba morate previdno rekonstituirati s 3,5 ml 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje.
In addition, when bortezomib is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these products should be considered in the event of toxicities according to the recommendations in the Summary of Product Characteristics.
Kadar dajemo bortezomib v kombinaciji z drugimi kemoterapevtiki je v primeru pojava toksičnosti potrebno razmisliti o zmanjšanju odmerka teh zdravil, skladno z njihovimi Povzetki glavnih značilnosti zdravil.
CLINICAL PARTICULARS
Samostojno zdravljenje
Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection
Bortezomib Fresenius Kabi 3,5 mg prašek za raztopino za injiciranje
Dehydration, Hypokalaemia*, Hyponatraemia*, Blood glucose abnormal*, Hypocalcaemia*, Enzyme abnormality*
Pogosti dehidracija, hipokaliemija*, hiponatriemija*, nenormalne koncentracije glukoze v krvi*, hipokalciemija*, encimske motnje*
Patients with moderate or severe hepatic impairment should be started on bortezomib at a reduced dose of 0.7 mg/m per injection during the first treatment cycle, and a subsequent dose escalation to 1.0 mg/m or further dose reduction to 0.5 mg/m may be considered based on patient tolerability (see table 6 and sections 4.4 and 5.2).
Zmanjšati odmerek bortezomiba v prvem ciklu zdravljenja na 0,7 mg/m Na osnovi bolnikovega prenašanja zdravljenja je treba pretehtati možnost povečanja odmerka na 1,0 mg/m ali zmanjšanja odmerka na 0,5 mg/m huda
Immune system disorders Uncommon Angioedema
Organski sistem Pogostnost Neželeni učinek Žilne bolezni
#, Stevens-Johnson syndrome Dermatitis*, Hair disorder*, Petechiae, Ecchymosis, Skin lesion, Purpura, Skin mass*, Psoriasis, Hyperhidrosis, Night sweats, Decubitus ulcer
#, dermatitis*, bolezni las*, petehije, ehimoze, spremembe na koži, purpura, kožna masa*, luskavica, hiperhidroza, nočno znojenje, dekubitusna razjeda akne*, mehurček*, motnje pigmentacije*
Bortezomib therapy should be withheld until symptoms of the toxicity have resolved to grade 1 or baseline.
Zdravljenje z bortezomibom je treba prekiniti, dokler se simptomi toksičnosti ne povrnejo na 1. stopnjo ali stanje pred začetkom zdravljenja.
Uncommon Muscle twitching, Joint swelling, Arthritis*, Joint stiffness, Myopathies*,Sensation of heaviness
Občasni trzanje mišic, otekanje sklepov, artritis*, okorelost sklepov, miopatije*, občutek teže
The median age of the patients in the study was 71 years, 50% were male, 88% were Caucasian and the median Karnofsky performance status score for the patients was 80.
Mediana starost bolnikov v študiji je bila 71 let, 50 % sodelujočih je bilo moških, 88 % belcev.
• Severe allergic reaction (anaphylactic reaction) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse
bolečino ali tiščanje v prsih in/ali omotico/omedlevico, hudo srbenje kože ali dvignjene bulice na koži, otekanje obraza, ustnic, jezika in/ali grla, kar lahko povzroči oteženo požiranje, kolaps
• Platelet counts should be ≥ 70 x 10 9/l and the absolute neutrophils count should be
• Število trombocitov mora biti ≥ 100.000 celic/μl in celokupno število nevtrofilcev (ANC
HR
g
Change bortezomib treatment schedule to 1.3 mg/m once per week.
zmanjšajte odmerek bortezomiba na 1,0 mg/m ali spremenite shemo zdravljenja z bortezomibom na odmerek 1,3 mg/m enkrat na teden.